biotech investing argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
biotech investing argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
biotech investing argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
biotech investing argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
biotech investing Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
biotech investing argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
biotech investing argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
biotech investing argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
biotech investing argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
biotech investing argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
biotech investing argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
Heliostar Metals to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 14
